🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

RecruitingPhase 2Ages 18 Years - 70 YearsAllInventisBio Co., Ltd
NCT07311200 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The patient voluntarily participates in this study after full informed consent. * The age is 18 years ≤ age ≤ 70 years, regardless of gender. * Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening. * SLEDAI-2K total score ≥ 8. * On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period. Exclusion Criteria: * History of infection as defined in the protocol. * Any of the medical diseases or disorders listed in the protocol. * Significant, uncontrolled or unstable disease in any organ.
💊

What it tests

  • D-2570
  • D-2570 Placebo
📍

Where

1 site
Linfen Central Hospital
Linfen, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy